SEC Form 3 filed by new insider Garner Thomas

$ACAD
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ACAD alert in real time by email
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Garner Thomas

(Last) (First) (Middle)
C/O ACADIA PHARMACEUTICALS, INC.
12830 EL CAMINO REAL, SUITE 400

(Street)
SAN DIEGO CA 92130

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
12/09/2024
3. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Commercial Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ Jennifer J. Rhodes, Attorney-in-Fact 12/10/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ACAD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ACAD

DatePrice TargetRatingAnalyst
2/11/2025$22.00Hold
Deutsche Bank
1/3/2025$23.00 → $20.00Buy → Neutral
Guggenheim
10/10/2024Mkt Perform
Raymond James
8/7/2024$28.00 → $20.00Overweight → Equal-Weight
Morgan Stanley
6/27/2024$31.00Outperform
BMO Capital Markets
3/12/2024$36.00 → $32.00Buy
Needham
3/12/2024$39.00 → $25.00Buy → Neutral
Mizuho
1/30/2024$40.00Outperform
Robert W. Baird
More analyst ratings

$ACAD
Press Releases

Fastest customizable press release news feed in the world

See more
  • Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 71,981 shares of common stock and 42,159 restricted stock units ("RSUs") to thirteen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $18.08 per share, Acadia's closing trading price on March 5, 2025, and will vest over four years, with 25% of

    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time Stifel 2025 Virtual CNS Forum Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time 24th Annual Needham Virtual Healthcare Conference Fireside Chat: Monday, April 7, 2025 at 10:15 a.m. Eastern Time Live webcasts of each fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceutic

    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

    -- Study supported FDA and Health Canada approvals of DAYBUE for treatment of Rett syndrome in patients ages two years and older -- Results consistent with Phase 3 LAVENDER™ and open-label LILAC™ studies Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age and older in the 12-week

    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ACAD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ACAD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ACAD
SEC Filings

See more

$ACAD
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for DAYBUE issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ACAD
Leadership Updates

Live Leadership Updates

See more
  • Acadia Pharmaceuticals Set to Join S&P SmallCap 600

    NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Jan 3, 2025 S&P SmallCap 600 Addition Acadia Pharmaceuticals ACAD Health Care Jan 3, 2025 S&P SmallCap 600 Deletion Independent Bank Group

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Banks
    Finance
  • Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

    – Seasoned commercial executive with more than 25 years pharmaceutical and biotech experience Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia's CEO, and serve on the executive leadership team. "Tom is an accomplished commercial executive with a demonstrated history of driving brand growth across a wide range of therapeutic areas

    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

    - Ms. Owen Adams brings over 25 years of pharmaceutical industry experience including senior commercial leadership roles with Bristol Myers Squibb and Johnson & Johnson Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. "We are excited to welcome Catherine Owen Adams as the new CEO of Acadia," said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. "Catherine is a proven global leader with a distinguished record of accomplishment of driving growth and innovation in the pharmaceutical industry. Her strategic vision, deep expertise, and unwavering

    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ACAD
Financials

Live finance-specific insights

See more
  • Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

    - 2024 total net product sales of $957.8 million, reflecting 32% revenue growth - Fourth quarter DAYBUE® (trofinetide) net product sales of $96.7 million and full year 2024 net product sales of $348.4 million - Fourth quarter NUPLAZID® (pimavanserin) net product sales of $162.9 million and full year 2024 net product sales of $609.4 million - Full year 2025 total revenue guidance of $1.03 to $1.095 billion including DAYBUE net sales guidance of $380 to $405 million and NUPLAZID net sales guidance of $650 to $690 million Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. "We closed 2024 on a s

    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

    Company to host conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 26, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until May 26, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email

    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

    - 3Q24 total revenues of $250.4 million, up 18% year-over-year - 3Q24 NUPLAZID® (pimavanserin) net product sales of $159.2 million, up 10% year-over-year - 3Q24 DAYBUE™ (trofinetide) net product sales of $91.2 million, up 36% year-over-year Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the third quarter ended September 30, 2024. "The success of Acadia's two growing commercial franchises is clearly reflected in our third quarter 2024 results, where we delivered $250.4 million in total revenues, putting us on track to reach an impressive milestone of more than $1 billion in annualized sales in 2025," said Catherine Owen Adams, Chief Executive Officer.

    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ACAD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more